Drug Profile
Cilgavimab/tixagevimab - AstraZeneca
Alternative Names: AZD 7442; AZD 8895 + AZD 1061; Cilgavimab + tixagevimab; COV2-2196 + COV2-2130; EVUSHELD; Tixagevimab + Cilgavimab; Tixagevimab/CilgavimabLatest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Vanderbilt University
- Developer AstraZeneca
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 07 Nov 2023 AstraZeneca terminates a phase-II clinical trial in COVID-2019 infections (In adolescents, In adults, In the elderly, Prevention) in the USA (IM) as sponsor terminated after review of FDA's request to halt further dosing (EudraCT2022-001014-20) (NCT05375760)
- 11 Oct 2023 Adverse events data from a phase III STORM CHASER trial in COVID-2019 infections presented at the IDWeek 2023 (IDW-2023)
- 11 Oct 2023 Final adverse events data from the phase III PROVENT trial in COVID-19 infections presented in IDWeek-2023 (IDW-2023)